UV Wavelength Selection in Stability-Indicating HPLC Methods

A stability-indicating assay (SIA) for drug substances or drug products is a cornerstone of pharmaceutical development and quality control. With few exceptions, SIA employs reversed-phase liquid chromatography with ultraviolet detection (RPLC–UV) using an acidified mobile phase. This approach provides excellent reproducibility, reliable mass balance, and highly precise UV detection (typically 0.2–0.5% RSD), which supports tight assay specifications for drug substances. While SIA method development has been extensively discussed in the literature,^1,2 the rationale for wavelength selection is less frequently addressed.

Figure 1 shows examples of UV spectra and mass spectra of six small-molecule new chemical entities (NCEs). NCEs are typically synthesized by medicinal chemists from structural motifs using principles of structure–activity relationships to optimize binding to the molecular target while reducing safety concerns.³ All six molecules are chromophoric, displaying one or two λmax values.

Most small-molecule drugs contain chromophores that absorb in the UV/visible range, including aromatic rings, conjugated systems, carbonyl groups, and nitro or heteroaromatic moieties. The majority are also basic compounds⁴ and are analyzed under acidic conditions (pH 2–4) to suppress silanol interactions and minimize peak tailing.

The six NCEs in Figure 1 show prominent singly or doubly charged base peaks at M+1 and (M+2)/2 under positive electrospray ionization (ESI+) in acidic mobile phase A (MPA). The high-performance liquid chromatography (HPLC) and mass spectrometry (MS) conditions used to generate these spectra are described elsewhere.⁵ Let us focus on the second NCE in our first method development case study, which has a molecular weight of 457 Da and a λmax of 284 nm.

Case Study 1: λmax as the Primary Monitoring Wavelength: Rationale and Lifecycle Implications

The default and often optimal choice for UV monitoring is the API λmax, as it maximizes sensitivity to both the API and structurally related impurities, which frequently share similar chromophores. Figure 2 shows an ultra-high-pressure liquid chromatography (UHPLC) stability-indicating assay (SIA) chromatogram of a retention time marker solution of the API spiked with its expected related substances. The process-scale-up chemistry for this NCE with three chiral centers, an AKT inhibitor, and the analytical chemistry effort supporting its clinical development are described elsewhere.^1,6 The salient features of this UHPLC method, along with subsequent adjustments during lifecycle management, are summarized below.

A monitoring wavelength of 280 nm, close to the API λmax, was selected with a spectral bandwidth of 4 nm. This choice provided high sensitivity for the API and four related substances, including diastereomers (SRS and RRR) and degradation products (M416 and M235).

Injection volume was adjusted to achieve an API peak height of approximately 1.5 absorbance units (AU), enabling a limit of quantitation (LOQ) of 0.05% and meeting the International Council for Harmonization (ICH) Q3A(R2) requirements for impurity reporting. To preserve detector linearity, API absorbance was maintained below 2.0 AU.

Normalized HPLC area percentage was used for quantification in early development, assuming that the relative response factors (RRFs, or the response ratio of the impurity versus the API) were unity. This assumption was later refined as reference standards became available for specific degradants with distinct chromophoric properties (the ketone degradant and the des-isopropyl degradant). A secondary data channel at 220 nm was collected to monitor less-chromophoric impurities and support process development.

During later lifecycle stages (phase 2b), the MPA was modified to a phosphate buffer at pH 3.7, and the detection wavelength was shifted to 224 nm to improve sensitivity for a good manufacturing practice (GMP) starting material (the Boc-β-amino acid) with limited UV absorbance at 280 nm. Although this change precluded compatibility with mass spectrometry, it was acceptable for late-stage quality control applications.

This case study demonstrates that λmax is an effective first choice for wavelength selection, providing sensitivity, selectivity, and flexibility across development stages. Strategic wavelength adjustments can be used later to address emerging analytical or regulatory needs.

Case Study 2: Selection of a Far-UV Detection Wavelength

In the second case study, an NCE intended for a good laboratory practice (GLP) toxicological evaluation study exhibited low molar absorptivity at its λmax (258 nm).⁷ Using this wavelength would have required high sample loading, resulting in excessive peak tailing and compromised chromatographic performance.

Instead, a far-UV wavelength of 220–230 nm was evaluated. Although concerns are sometimes raised about detector robustness when operating on the slope of a UV spectrum, modern UV detectors provide excellent reproducibility and stability in this region. A wavelength of 230 nm was selected, and balanced-absorbance trifluoroacetic acid (TFA) mobile phases⁸ were used to minimize gradient-related baseline shifts, as shown in Figure 3. The resulting method, developed and validated on a polar-embedded amide column, demonstrated strong sensitivity and robustness (including wavelength changes), with an LOQ of 0.05% for the immediate precursor impurity.⁷ This example illustrates that far-UV detection is a practical and effective strategy for compounds with no or weak λmax values.

Case Study 3: Use of a Secondary λmax for Drug Product Analysis

The final case study involved the development of a stability-indicating HPLC method for an over-the-counter (OTC) senna-based laxative derived from a natural product. The goal was to supplement an existing USP spectrophotometric assay with a more informative, component-resolved HPLC method.^1,9

The UV spectrum of sennosides showed three absorption maxima at approximately 212 nm, 268 nm, and 338 nm (Figure 4). While 212 nm showed strong absorbance, it was influenced by the mobile phase under HPLC conditions with MPA, with an end absorbance (cutoff) below 220 nm. An initial detection wavelength of 270 nm was selected, enabling separation and quantification of eight major senna components in tablet formulations (Figure 4). Potency values derived by summing these components correlated well with USP method results.

However, application of the method to syrup formulations proved challenging due to significant interference from preservatives, including sorbic acid and parabens, which absorb strongly at 270 nm (Figure 5). Rather than redeveloping the method, the monitoring wavelength was shifted to 340 nm, where the preservatives exhibited no absorbance (Figure 6). This change effectively eliminated interference, allowing the method to be applied to syrup formulations with only adjustments to relative response factors (RRFs).

This case study demonstrates how selecting a secondary λmax can resolve matrix or preservative interferences and extend method applicability without extensive redevelopment.

Summary and Conclusions

Selecting an appropriate UV-monitoring wavelength is a critical yet often underappreciated aspect of HPLC method development. While the API λmax remains the standard and preferred choice, these case studies illustrate situations in which additional adjustments are often needed in the late-stage method and when alternative strategies are more effective. Far-UV detection can improve sensitivity for compounds with weak chromophores, and secondary λmax selection can eliminate interferences in complex matrices.

A thoughtful and flexible approach to wavelength selection enhances method robustness, supports regulatory compliance, and facilitates efficient lifecycle management of analytical procedures.

Acknowledgments

I gratefully acknowledge the valuable technical and editorial contributions from Matt Mullaney (retired); Alice Krumenaker (retired from Hovione); Mike Shifflet (Kenvue); Leon Doneski (Arcutis Biotherapeutics); Mengling Wong (Genentech); Jacob Fairchild (Kao Specialties Americas); and Jonnie Shackman (Bristol Myers Squibb).

References

1. Dong, M. W. HPLC and UHPLC for Practicing Scientists, 2nd ed.; Wiley: Hoboken, NJ, 2019; Chapters 5-6, 9-10.
2. Dong, M. W.; Huynh-Ba, K.; Ayers, J. T. Development of Stability-Indicating Analytical Procedures by HPLC: An Overview and Best Practices. LCGC North Am. 2020, 38 (8), 440-455.
3. Dong, M. W. Small-Molecule Drug Discovery (SMDD): Processes, Perspectives and Candidate Selection. LCGC North Am. 2022, 40 (8), 344-350. DOI: 10.56530/lcgc.na.dd8277z9
4. HPLC in Pharmaceutical Analysis Series, EP-1: Why Are Most Drugs Basic? YouTube. ((uploaded 2025-11-05; accessed 2026-04-14) https://youtu.be/jSRIEXYAdyM
5. Dong, M. W. A Universal Reversed-Phase HPLC Method for Pharmaceutical Analysis. LCGC North Am. 2016, 34 (6), 408-419.
6. Remarchuk, T.; St-Jean, F.; Carrera, D. et al. Synthesis of Akt Inhibitor GDC-0068 (Ipatasertib). Part II. Total Synthesis and First Kilogram Scale-up. Org. Process Res. Dev. 2014, 18 (12), 1652–1666. DOI:10.1021/op500270z
7. HPLC in Pharmaceutical Analysis Series, EP-27: The Story of My First HPLC Method Development and Validation of a New Chemical Entity. YouTube (uploaded 2026-02-12; accessed 2026-04-14) https://youtu.be/IDzsLpyYxuUhttps://youtu.be/IDzsLpyYxuU
8. HPLC in Pharmaceutical Analysis Series, EP-17: What Is a Balanced Absorbance MP, and How to Use It? YouTube. https://youtu.be/5o4_d4azPMc
9. United States Pharmacopeia. Senna Leaf. USP–NF Monographs, Dietary Supplement Monographs. Rockville, MD, 2017. DOI: 10.31003/USPNF_M74880_01_01